Managing Chronic Tendon Pain by Metformin
Tendinopathy, Chronic Pain, Achilles Tendinopathy
About this trial
This is an interventional treatment trial for Tendinopathy focused on measuring Achilles Tendon, Metformin, Achilles Tendinopathy, Chronic Pain
Eligibility Criteria
Inclusion Criteria: Willing and able to provide informed consent for participation Clinical diagnosis of Achilles tendinopathy Pain disability index score of between 20 - 70 points (0-100 scale VISA-A) Sonopalpation tenderness with tendon thickening and/or loss of fibrillary architecture. Ability to read, speak, and understand English Exclusion Criteria: Any intervention (corticosteroids or other orthobiologic intervention as injection) to targeted tissue within the last 6 months. Previous Achilles tendon surgery. Known platelet abnormality or hematological disorder. Presence of other conditions that might affect the functional scale of the indexed limb. Unwillingness to be randomized. Body Mass Index (BMI) greater than 30. Occult tear in the indexed tendon. Systemic inflammatory disease. Use of fluoroquinolone in the past 6 months. Subjects must not be pregnant or breastfeeding, or planning to become pregnant or breastfeed during the course of the trial Chronic kidney disease (eGFR <60) Diagnosis of diabetes mellitus or elevated HbA1c at screening (> 6.5) Unable to take an oral medication in a non crushable pill form Taking metformin presently or within the last 6 months History of allergy to metformin History of lactic acidosis or elevated lactate at screening (> 2.2) Severe Hepatic dysfunction Currently taking a diabetic medication such as sitagliptin, saxagliptin, linagliptin, alogliptin, sitagliptin with metformin Currently taking a Carbonic anhydrase inhibitor such as topiramate, zonisamide, acetazolamide, dichlorphenamide, methazolamide Currently taking cimetidine
Sites / Locations
- University of Pittsburgh
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Experimental
Placebo Group, Placebo Capsules
Treatment Group, Metformin Capsules
Placebo Group (n=20) Week 1: One placebo capsule (500 mg) daily Week 2: Two placebo capsules (1,000 mg) daily Week 3: Three placebo capsules (1,500 mg) daily Week 4-16: Four placebo capsules (2,000 mg) daily
Treatment Group (n=20) Week 1: One metformin ER capsule (500 mg) daily Week 2: Two metformin (ER) capsules (1,000 mg) daily Week 3: Three metformin (ER) capsules (1,500 mg) daily Week 4-16: Four metformin (ER) capsules (2,000 mg) daily